On Feb 11, 2025, the Global Platform for Access to Childhood Cancer Medicines (known as the Global Platform) announced that it had started distributing drugs to the six countries participating in the pilot phase of the initiative. The platform is a partnership between WHO and St Jude Children’s Research Hospital, which is providing technical support… Continue reading [News] Global Platform for childhood cancer medicine access starts distributing drugs
Tag: Pediatric Cancer
[News] Call to prioritise access to essential cancer medicines in Latin America and the Caribbean
On Feb 3, 2025, the Pan American Health Organization (PAHO) issued a statement calling on countries in Latin America and the Caribbean to prioritise access to essential cancer medicines. The statement noted that there are more than 4 million new cases of cancer every year in the Americas and over 1·4 million deaths. Patients do… Continue reading [News] Call to prioritise access to essential cancer medicines in Latin America and the Caribbean
Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL
Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Reply to “Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?”
Cancer, Volume 131, Issue 4, 15 February 2025.
Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma: How much is enough?
Cancer, Volume 131, Issue 4, 15 February 2025.
Reply to “Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?”
Cancer, Volume 131, Issue 4, 15 February 2025.
Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma: How much is enough?
Cancer, Volume 131, Issue 4, 15 February 2025.
Research discovery halts childhood brain tumor before it forms
A research team has identified a critical event driving tumor growth in a type of medulloblastoma — and a way to block it.